Costabel U, Hunninghake GW (1999) ATS/ERS/
WASOG statement on sarcoidosis. Sarcoidosis State-
ment Committee. American Thoracic Society.
European Respiratory Society. World Association for
Sarcoidosis and Other Granulomatous Disorders. Eur
Respir J 14:735–
Cross SS, Yang Z, Brown NJ, Balasubramanian SP,
Evans CA, Woodward JK, Neville-Webbe HL, Lippitt
JM, Reed MW, Coleman RE, Holen I (2006)
Osteoprotegerin (OPG) -a potential new role in the
regulation of endothelial cell phenotype and tumour
angiogenesis? Int J Cancer 118:1901–
Crowley LE, Herbert R, Moline JM, Wallenstein S,
Shukla G, Schechter C, Skloot GS, Udasin I, Luft
BJ, Harrison D, Shapiro M, Wong K, Sacks HS,
Landrigan PJ, Teirstein AS (2011) ‘Sarcoid like’ gran-
ulomatous pulmonary disease in World Trade Center
disaster responders. Am J Ind Med 54:175–
Goswami S, Sharma-Walia N (2015) Osteoprotegerin
secreted by inflammatory and invasive breast cancer
cells induces aneuploidy, cell proliferation and angio-
genesis. BMC Cancer 15:
Kieszko R, Krawczyk P, Jankowska O, Chocholska S,
Kro ́l A, Milanowski J (2007) The clinical significance
of interleukin 18 assessment in sarcoidosis patients.
Respir Med 101:722–
Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I,
Keaney JF, Rong J, Corey D, Hoffmann U, Fox CS,
Vasan RS, Benjamin EJ, O’Donnell CJ, Kathiresan S
(2010) Biomarkers of the osteoprotegerin pathway:
clinical correlates, subclinical disease, incident car-
diovascular disease, and mortality. Arterioscler
Thromb Vasc Biol 30:1849–
Liu DH, Yao YT, Cui W, Chen K (2010) The association
between interleukin-18 and pulmonary sarcoidosis: a
meta-analysis. Scand J Clin Lab Invest 70:428–
Müller-Quernheim J (1998) Sarcoidosis:
immunopathogenetic concepts and their clinical appli-
cation. Eur Respir J 12:716–
Piotrowski WJ, Kiszałkiewicz J, Go ́rski P, Antczak A,
Go ́rski W, Pastuszak-Lewandoska D, Migdalska-
Se ̨k M, Doman ́ska-Senderowska D, Nawrot E,
Czarnecka KH, Kurmanowska Z, Brzezian ́ska-Lasota
E (2015) Immunoexpression of TGF-β/Smad and
VEGF-A proteins in serum and BAL fluid of sarcoid-
osis patients. BMC Immunol 16:
Reinhard H, Lajer M, Gall MA, Tarnow L, Parving HH,
Rasmussen LM, Rossing P (2010) Osteoprotegerin
and mortality in type 2 diabetic patients. Diabetes
Care 33:2561–
Sandberg WJ, Yndestad A, Oie E, Smith C, Ueland T,
Ovchinnikova O, Robertson AK, Muller F, Semb AG,
Scholz H, Andreassen AK, Gullestad L, Damas JK,
Froland SS, Hansson GK, Halvorsen B, Aukrust P
(2006) Enhanced T-cell expression of RANK ligand
in acute coronary syndrome: possible role in plaque
destabilization. Arterioscler Thromb Vasc Biol
26:857–
Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R,
Gullestad L, Kastelein JJ, Khaw KT, Boekholdt SM
(2009) Osteoprotegerin and soluble receptor activator
of nuclear factor-kappaB ligand and risk for coronary
events: a nested case-control approach in the prospec-
tive EPIC-Norfolk population study 1993–2003.
Arterioscler Thromb Vasc Biol 29:975–
Shigehara K, Shijubo N, Ohmichi M, Takahashi R, Kon S,
Okamura H, Kurimoto M, Hiraga Y, Tatsuno T,
Abe S, Sato N (2001) IL-12 and IL-18 are increased
and stimulate IFN-gamma production in sarcoid lungs.
J Immunol 166:642–
Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY,
Müller-Quernheim J (2014) Sarcoidosis. Lancet
9923:1155–
Zielonka TM, Demkow U, Białas B, Filewska M,
Zycinska K, Radzikowska E, Szopin ́ski J, Skopin ́ska-
Ro ́zewska E (2007) Modulatory effect of sera from
sarcoidosis patients on mononuclear cell-induced
angiogenesis. J Physiol Pharmacol 58:753–Osteoprotegerin/sRANKL Signaling System in Pulmonary Sarcoidosis... 7